Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody. (July 2019)

• Record Type: Journal Article
• Authors: Saiki, Masafumi; Yoshizawa, Takahiro; Dotsu, Yosuke; Ariyasu, Ryo; Koyama, Junji; Sonoda, Tomoaki; Uchibori, Ken; Nishikawa, Shingo; Kitazono, Satoru; Yanagitani, Noriko; Horiike, Atsushi; Nishio, Makoto
• Is Part Of: Lung cancer. Volume 133(2019)
• Page Start: 4
• Page End: 9
• Publication Date: 2019-07
• Subjects: PD-1 programmed cell death 1 -- ADA adenosine deaminase -- NSCLC non-small cell lung cancer -- SCLC small cell lung cancer -- Adeno adenocarcinoma -- Sq squamous cell carcinoma -- PD-L1 PD-1 ligand 1 -- ECOG PS Eastern Cooperative Oncology Group performance status -- EGFR epidermal growth factor receptor -- ALK anaplastic lymphoma kinase -- PR partial response -- SD stable disease -- PD progressive disease -- A2AAR A2A adenosine receptor; Lung cancer -- Immune checkpoint inhibitor -- Anti-programmed cell death-1 therapy -- Adenosine deaminase; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2019.04.022
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: Serum ADA increased from baseline in the patients who response for anti-PD-1 therapy. Serum ADA decreased from baseline regardless of response in the chemotherapy group. Increases in serum ADA were associated with longer PFS in anti-PD-1 group. Abstract: Objective: Serum adenosine deaminase (ADA) activity is a marker of immune reaction to several diseases. We evaluated changes in serum ADA in patients with lung cancer undergoing chemotherapy or anti-programmed cell death-1 (PD-1) therapy to examine the correlation between serum ADA and the therapy efficacy. Materials and methods: We assessed 50 patients with advanced lung cancer receiving chemotherapy or anti-PD-1 therapy. Serum ADA was measured before and on day 7 of the first treatment cycle and day 0 of subsequent cycles. Correlations between ADA change and efficacy of treatment were evaluated. Results: Of the 50 patients, 20 were treated with chemotherapy and 30 were treated with anti-PD-1 therapy. Serum ADA decreased significantly between baseline and day 7 of the first cycle in patients undergoing chemotherapy, regardless of response (partial response [PR] or stable disease [SD]: −23% [−38 to +32; p = 0.002]; progressive disease [PD]: −12% [−42 to +6; p = 0.500]). Conversely, in patients undergoing anti-PD-1 therapy, serum ADA increased significantly between baseline and 7 days after the first dose and before subsequent doses in patients who had PR or SD. (day 7 of first cycle: +6% [−10 to +34; p = 0.034], day 0 of second cycle: 8% [−5 to +37; p = 0.002], day 0 of third cycle: 9% [−3 to +55; p = 0.002]). However, serum ADA did not significant change in PD patients undergoing anti-PD-1 therapy. Furthermore, early increases in serum ADA were associated with longer progression-free survival in patients receiving anti-PD-1 therapy ( p = 0.006). Conclusion: Changes in serum ADA could be used to predict clinical benefit from anti-PD-1 therapy in patients with lung cancer. The association between changes in serum ADA and the efficacy of ant-PD-1 therapy thus remains inconclusive and requires further study.